FDA rejects Arpida's iclaprim for cSSSI

26 January 2009

The US Food and Drug Administration says it needs more evidence of efficacy before it can approve Swiss firm Arpida's intravenous iclaprim  for the treatment of complicated skin and skin structure infections.

Commenting on the complete response letter, company chief executive  Jurgen Raths said: "after the negative recommendation of the Advisory  Committee of last November, the FDA opinion comes as no surprise. We  now aim to develop a viable roadmap to approval in close consultation  with the FDA. The drastic cost saving measures that we've recently  implemented should buy us sufficient time to consider and develop  strategic options for progressing iclaprim's development."

Last year, Arpida announced plans to reduce its workforce by up to 60  employees, while consulting external experts to determine the future  development of iclaprim (Marketletter December 8, 2008).

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight